C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5591-5596

  Baba, Hiroyuki ^a   Kuwabara, Koki ^a   Ishiguro, Toru ^a   Hatano, Satoshi ^a   Matsuzawa, Takeaki ^a   Fukuchi, Minoru ^a   Kumagai, Yoichi ^a   Ishibashi, Keiichiro ^a   Mochiki, Erito ^a   Ishida, Hideyuki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; Cut off value; Prognosis; Stage IV gastric cancer

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LIFE EXPECTANCY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SHORT TERM SURVIVAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; TUMOR LOCALIZATION; VERY ELDERLY;

EID: 84891458296     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lee HK, Yang HK, Kim WH, Lee KU, Choe KJ and Kim JP: Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 88(10): 1408-1412, 2001.
2. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, Ono H, Tanabe S and Kaminishi M: Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 16(1): 1-27, 2013.
3. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3). Gastric Cancer 14(2): 113-123, 2011.
4. Sano T and Aiko T: New Japanese classifications and treatment guidelines for gastric cancer: revision, concepts and major revised points. Gastric Cancer 14(2): 97-100, 2011.
5. Abramovitch R, Marikovsky M, Meir G and Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 79(9-10): 1392-1398, 1999.
6. Canna K, Himly M, McMillan DC, Smith GW, McKee RF, McArdle CS and McNicol AM: The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis 10(7): 663-667, 2008.
7. Black S, Kushner I and Samols D: C-reactive protein. J Biol Chem 279(47): 487-490, 2004.
8. Wakuda R, Miki C and Kusunoki M: Autoreactivity against interleukin 6 as a risk factor in elderly patients with colorectal carcinoma. Arch Surg 136(11): 1274-1279, 2001.
9. Sobin LH, Gospodarowicz M and Wittelkind C: Stomach. In: International Union Against Cancer. TNM Classification of Malignant Tumours-7th edition. New York, Wiley-Blackwell, pp. 84-95, 2009.
10. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer 1 (1): 10-24, 1998.
11. Du Clos TW and Mold C: C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 30(3): 261-277, 2004.
12. Nozoe T, Matsumata T and Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 23(3): 263, 2000.
13. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R and Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92(1): 21-23, 2005.
14. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ and Stuart RC: An elevated C-reactive protein concentration, prior to surgery predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 94(11): 1568-1571, 2006.
15. Elahi MM, McMillan DC, McArdle CS, Angerson WJ and Sattar N: Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 48(2): 171-173, 2004.
16. Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS and McMillan DC: Evaluation of the relationship between the systematic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 96(6): 891-895, 2007.
17. Ramsey S: The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer. Mol Diagn Ther 13(5): 277-281, 2009.
18. Ramsey S, Lamb GW, Aitchison M and McMillan DC: The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 95(8): 1076-1080, 2006.
19. Koike Y, Miki C, Okunaga Y, Yokoe T, Toiyama Y, Tanaka K, Inoue Y and Kusunoki M: Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98(7): 540-544, 2008.
20. Ikeda M, Natsugoe S, Ueno S, Baba M and Aikou T: Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238 (2): 197-202, 2003.
21. Hilmy M, Bartlett JM, Underwood MA and McMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 92(4): 625-627, 2005.
22. Lamb GW, McMillan DC, Ramsey S and Aitchison M: The relationship between the preoperative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell carcinoma. Br J Cancer 94(6): 781-784, 2006.
23. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J and Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110(6): 1241-124, 2006.
24. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG and McArdle CS: Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 90(9): 1707-1709, 2004.
25. Nozoe T, Matsumata T, Kitamura M and Sugimachi K: Significance of preoperative elevation in serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176 (4): 335-338, 1998.
26. McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection for colorectal cancer. Br J Surg 90(2): 215-219, 2003.
27. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG and McMillan DC: The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer 94(12): 1833-1836, 2006.
28. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG and McArdle CS: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 170(4): 319-322, 1995.
29. Nozoe T, Matsumata T and Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 23(3): 263-266, 2000.
30. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D and Sinha R: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66(4): 2483-2487, 2006.
31. Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6): 1028-1030, 2003.
32. Toiyama Y, Miki C, Inoue Y Tanaka K, Mohri Y and Kusunoki M: Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med 2(1): 95-101, 2011.